A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Àkótán ìròyìn
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Tẹ̀lé ìròyìn tuntun láti ọ̀dọ̀ àwọn olùtẹ̀jáde tó ṣeé gbẹ́kẹ̀lé pẹ̀lú àkótán kúkúrú. Ṣí ìjápọ̀ orísun àtilẹ̀wá fún àlàyé.